Cleared Traditional

TCD OR TCD NEUROPATHY STAR (K944234) - FDA 510(k) Clearance

Class I Neurology device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1995
Decision
189d
Days
Class 1
Risk

K944234 is an FDA 510(k) clearance for the TCD OR TCD NEUROPATHY STAR. Classified as Discriminator, Two-point (product code GWI), Class I - General Controls.

Submitted by Jcm Management & Planning Co. (Wilmington, US). The FDA issued a Cleared decision on March 8, 1995 after a review of 189 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1200 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Jcm Management & Planning Co. devices

Submission Details

510(k) Number K944234 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 31, 1994
Decision Date March 08, 1995
Days to Decision 189 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
41d slower than avg
Panel avg: 148d · This submission: 189d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GWI Discriminator, Two-point
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 882.1200
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.